Raptor Announces Phase 2b Trial of RP103 for NAFLD in Children Meets Enrollment Target
January 13, 2014 at 07:04 AM EST
Raptor Pharmaceutical (Nasdaq: RPTP ) today announced that its Phase 2b clinical trial, to evaluate the safety and potential efficacy of RP103 delayed-release cysteamine bitartrate as a prospective treatment of non-alcoholic fatty liver disease (NAFLD) in children, has met its enrollment target. See full press
